Anixa Biosciences Advances Ovarian Cancer CAR-T to Highest Dose
SAN JOSE, California, July 6, 2026 Anixa Biosciences, Inc. and Moffitt Cancer Center have announced a significant milestone in...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN JOSE, California, July 6, 2026 Anixa Biosciences, Inc. and Moffitt Cancer Center have announced a significant milestone in...
LOS ANGELES, Calif., June 18, 2026 TORL BioTherapeutics has reported encouraging preliminary Phase 1 clinical data for its investigational...
